hyoscyamine sulfate

(redirected from NuLev)



hyoscyamine sulfate

Anaspaz, Hyospaz, Levsin, Levsin/SL, Symax, Symax-SL, Symax-SR

Pharmacologic class: Anticholinergic

Therapeutic class: Antispasmodic

Pregnancy risk category C


Competitively inhibits acetylcholine action at autonomic nerve sites, relaxing smooth muscle and decreasing glandular secretions



Tablets: 0.15 mg

hyoscyamine sulfate

Capsules (timed-release): 0.375 mg

Elixir: 0.125 mg/5 ml

Injection: 0.5 mg/ml

Oral solution: 0.125 mg/ml

Tablets: 0.125 mg

Tablets (extended-release): 0.375 mg

Tablets (orally disintegrating): 0.125 mg

Tablets (sublingual): 0.125 mg

Indications and dosages

Adjunct in GI tract disorders; pain and hypersecretion in pancreatitis; cystitis; renal colic; infant colic; acute rhinitis; rigidity, tremors, and hyperhidrosis in Parkinson's disease; partial heart block due to vagal activity

Adults and children ages 12 and older: 0.125 to 0.25 mg (sulfate) P.O. or S.L. two to four times daily, or 0.375 to 0.75 mg (extended-release sulfate) P.O. q 12 hours, or 0.25 to 0.5 mg (sulfate) subcutaneously, I.M., or I.V. two to four times daily p.r.n.

Children ages 2 to 12: In children weighing approximately 50 kg (110 lb), 0.125 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 20 kg (40 lb), 0.0625 mg P.O. (sulfate); in children weighing approximately 10 kg (22 lb), 0.031 to 0.033 mg (sulfate) P.O. Don't exceed 0.75 mg/day.

Children ages 2 and younger: In children weighing approximately 7 kg (15 lb), 0.025 (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 5 kg (11 lb), 0.0208 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 3.4 kg (7.5 lb), 0.0167 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 2.3 kg (5 lb), 0.0125 mg (sulfate) P.O. q 4 hours p.r.n.

Before endoscopy or hypotonic duodenography

Adults: 0.25 to 0.5 mg (sulfate) subcutaneously, I.M., or I.V. 5 to 10 minutes before procedure

Preoperatively to inhibit salivation and excessive respiratory secretions

Adults and children older than age 2: 5 mcg/kg (sulfate) I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia induction

Muscarinic toxicity

Adults: 1 to 2 mg (sulfate) I.V. Additional 1-mg doses may be given I.M. or I.V. q 3 to 10 minutes until muscarinic signs and symptoms subside; doses may be repeated if needed. Patient may need up to 25 mg during first 24 hours. For maintenance, 0.5 to 1 mg P.O. at intervals of several hours until signs and symptoms disappear.


• Hypersensitivity to anticholinergics, alcohol, sulfites, or tartrazine

• Angle-closure glaucoma, synechia

• GU or GI obstructive disease, severe ulcerative colitis

• Renal or hepatic disease

• Neonates or premature infants


Use cautiously in:

• cardiovascular disease, prostatic hypertrophy, reflux esophagitis, brain damage, autonomic neuropathy, hyperthyroidism, glaucoma, Down syndrome, spastic paralysis

• elderly patients

• pregnant (safety not established) or breastfeeding patients

• infants and small children.


• Administer 30 to 60 minutes before meals and at bedtime.

• Give bedtime dose at least 2 hours after last evening meal or snack.

• Be aware that hyoscyamine is given P.O. only, whereas hyoscyamine sulfate may be given P.O., I.M., I.V., sublingually, or subcutaneously.

• Know that a cholinerase reactivator (pralidoxime) is given concomitantly to treat muscarinic toxicity.

Adverse reactions

CNS: confusion, excitement, nervousness, dizziness, light-headedness, headache, insomnia

CV: palpitations, tachycardia

EENT: blurred vision, cycloplegia, increased intraocular pressure, mydriasis, photophobia

GI: nausea, vomiting, constipation, bloating, dry mouth, paralytic ileus

GU: urinary hesitancy or retention, erectile dysfunction, lactation suppression

Skin: flushing, decreased sweating, urticaria, local irritation (with I.M., I.V., or subcutaneous use)

Other: altered taste, allergic reactions (including fever), heat intolerance, anaphylaxis


Drug-drug. Amantadine, antihistamines, antiparkinsonian drugs, disopyramide, glutethimide, meperidine, procainamide, quinidine, tricyclic antidepressants: increased anticholinergic effects

Antacids: decreased hyoscyamine absorption

Atenolol: increased atenolol effects

Ketoconazole: interference with absorption of both drugs

Methotrimeprazine: increased risk of extrapyramidal effects

Phenothiazines: decreased phenothiazine effects, increased anticholinergic effects

Drug-herbs. Jimsonweed: adverse cardiovascular effects

Patient monitoring

• Watch for adverse reactions.

• Check for mental status changes, such as confusion.

• Evaluate fluid intake and output.

• Assess patient's response to temperature changes (especially hot weather). Drug may cause heat intolerance, predisposing patient to heat stroke.

Patient teaching

• Tell patient to take on empty stomach 30 to 60 minutes before meals and at least 2 hours after last evening meal or snack.

• Instruct patient with urinary hesitancy to empty bladder before taking.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.


hy·o·scy·a·mine sul·fate

an antispasmodic, hypnotic, and sedative, also used in parkinsonism to relieve tremor, rigidity, and excessive salivation.

hy·o·scy·a·mine sul·fate

(hīō-sīă-mēn sŭlfāt)
Antispasmodic, hypnotic, and sedative, also used in parkinsonism to relieve tremor, rigidity, and excessive salivation.

hyoscyamine sulfate

n brand names: Anaspaz, Levsin, Levsinex, Gastrosed;
drug class: anticholinergic;
action: inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites;
uses: treatment of peptic ulcer disease in combination with other drugs; other gastrointestinal disorders; other spastic disorders such as parkinsonism; also preoperatively to reduce secretions.
References in periodicals archive ?
The manufacturing requirements of CIMA's pharmaceutical company partners and CIMA's resulting product sales for Remeron Soltab, Zomig-ZMT and NuLev have been subject to normal market roll-out patterns following the launch of these products in this year's first and second quarters.
For this reason, the Company believes sales of Remeron SolTab, Zomig-ZMT and Rapimelt, and NuLev should accelerate during the second half of 2001.